Four Trends Driving Pharma Biocatalysis Adoption

Biocatalysis has steadily gained traction in pharmaceutical manufacturing over the past two decades, but the field is now entering a new phase of maturity. What was once viewed as a specialized technique used in select cases is becoming a standard tool in the pharmaceutical process development toolkit.

Industry trends are expanding the role of biocatalysis in small-molecule API manufacturing and positioning it as a core component of modern process chemistry. They include:

1. Machine Learning Is Accelerating Pharma Biocatalysis

One of the most visible trends in pharma biocatalysis today is the growing use of machine learning (ML) to accelerate catalyst development. It has traditionally relied on iterative cycles of mutation and screening to improve catalytic performance. Although highly successful, these approaches can require substantial experimental effort. Computational biology tools are increasingly being used to guide these processes, helping scientists identify which mutations are most likely to improve activity, selectivity or stability.

ML models trained on experimental data can identify relationships among enzyme sequences, structures and catalytic performance. These insights enable researchers to prioritize promising variants earlier in the engineering cycle and reduce the number of experimental rounds required to reach a high-performing catalyst.

Importantly, these tools are not entirely new to the field. Some organizations have been integrating computational biology with enzyme engineering workflows for many years. As data sets grow and algorithms improve, these methods are becoming even more powerful, enabling faster optimization of enzymes that meet the demanding requirements of pharmaceutical manufacturing.

Speed is critical in drug development, where timelines from discovery to clinical production are tightly compressed. By helping teams engineer more efficient biocatalysts more quickly, ML-enabled design approaches can significantly shorten development timelines.

1. Biocatalysis Adoption Across Pharma and CDMOs

As the benefits of biocatalysis become more widely recognized, adoption is expanding across both pharmaceutical innovators and CDMOs. Large pharmaceutical companies increasingly incorporate enzymatic transformations into commercial manufacturing processes for small molecule active pharmaceutical ingredients (APIs). In many cases, these enzymes are produced at a substantial scale to support global drug supply.

At the same time, CDMOs are integrating biocatalysis capabilities into their process development offerings. This allows them to support partners seeking scalable, efficient synthetic routes and to implement enzymatic steps during scale-up and commercial manufacturing.

The result is a rapidly expanding ecosystem for enzyme-enabled pharmaceutical manufacturing. Specialized enzyme developers, process chemistry teams and manufacturing partners collaborate to design and implement scalable enzymatic processes. Some of these collaborations reach significant production volumes. In such cases, tens of tonnes of biocatalysts may be produced to support API manufacturing at a global scale.

1. Scaling with Sustainability and Process Efficiency Remain Key Drivers

Many traditional chemical transformations require multiple reaction steps, protecting groups, harsh reagents or precious-metal catalysts. These approaches can generate significant solvent use and chemical waste, particularly in complex asymmetric syntheses.

Biocatalysis offers an alternative route. Enzymes are inherently selective catalysts that operate under mild conditions, often enabling:

• Fewer synthetic steps
• Improved regio- and stereoselectivity
• Reduced use of hazardous reagents
• Lower solvent consumption

By simplifying reaction pathways and improving selectivity, enzymatic steps can reduce downstream purification requirements and improve overall process scalability and efficiency.

These advantages are increasingly important as pharmaceutical companies pursue greener manufacturing strategies and aim to reduce the environmental footprint of their processes. For many molecules, replacing traditional chemical steps with enzymatic transformations can deliver both sustainability benefits and operational efficiencies.

1. From Niche Solution to Standard Tool

Another major shift in the industry is the adoption of biocatalysis by pharmaceutical process chemists. In modern process development workflows, chemists often evaluate enzymatic and chemical routes in parallel. This integrated approach enables teams to identify the most scalable and efficient solution early in development, rather than retrofitting enzymatic steps later.

The broader availability of enzyme screening tools has also contributed to this shift. Off-the-shelf enzyme panels allow process development teams to rapidly test a range of catalysts against a target reaction without immediately investing in enzyme engineering.

In many cases, a commercially available enzyme can already meet early development requirements. When additional performance improvements are needed, such as higher activity, broader substrate tolerance or improved stability, directed enzyme evolution can then be applied to optimize the catalyst.

This “fit-for-purpose” approach allows companies to deploy biocatalysis quickly while retaining the flexibility to engineer tailored solutions as programs advance.

The Future of Biocatalysis

Biocatalysis is an increasingly established component of modern process development. Advances in ML-enabled enzyme engineering are accelerating catalyst optimization. Sustainability goals are encouraging companies to adopt greener manufacturing routes, and process chemists are incorporating enzymatic solutions earlier in development workflows.

As these trends continue, the role of biocatalysis in pharmaceutical manufacturing is set to expand further. Enzymes will increasingly complement traditional chemistry, enabling more scalable, sustainable routes to future medicines. For pharmaceutical developers, the key question is no longer whether biocatalysis can play a role in API synthesis, but how early it can be integrated to realize its full potential.